Simponi Aria (Golimumab) Approved for Juvenile Arthritis Types pJIA and jPsA
Recently, the Janssen Pharmaceutical Companies of Johnson & Johnson ("Janssen") announced the FDA approval of Simponi Aria (golimumab). The therapy is designed to treat pediatric patients (ages 2 or older)…
 
								 
								 
			
			
	 
			
			
	 
			
			
	 
			
			
	 
			
			
	 
			
			
	 
			
			
	 
			
			
	 
			
			
	 
															 
            